Saneian Hossein, Nasri Peiman, Heydari Ahmad, Sabzghabaee Ali Mohammad, Yazdi Maryam, Khademian Majid, Famouri Fatemeh
Department of Pediatrics, School of Medicine, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Imam Hossein Children's Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2024 Jul 29;13:61. doi: 10.4103/abr.abr_346_22. eCollection 2024.
Eating disorders in some infants can be due to the inability to reach a level of relaxation necessary to start the feeding process. Gabapentin (GB) has been proposed as a stabilizer of nerve function in improving this disorder. This study aimed to investigate the effect of GB on improving feeding resistance in infants aged 3-6 months.
This randomized, controlled, double-blind clinical trial was done on 64 infants aged 3-6 months with feeding resistance who were referred to the pediatric clinics and assigned to two groups of 32. The case group was given a dose of 5 mg/kg of GB in the first week, and if not too much sedation, it was increased to 10 mg/kg in the second week every 8 hours, whereas the control group received a placebo. The number of effective breastfeeding and the volume of formula in cc before and after 2 weeks of drug usage were recorded in both groups.
The number of breastfeeding sessions significantly had a higher increase in the GB group compared with placebo (median [IQR]: 1 [0,1] vs. 0 [0,1], = 0.005) as well as an increase in consumed formula volume (mean ± SD: 42.81 ± 24.49 vs. 18.67 ± 14.57, = 0.003).
Considering the significant increase in formula consumption and the number of breastfeeding sessions in the GB group, it is possible to use this drug as a nerve-stabilizer and pain reducer to treat this disorder.
一些婴儿的进食障碍可能是由于无法达到启动进食过程所需的放松程度。加巴喷丁（GB）已被提议作为改善这种障碍的神经功能稳定剂。本研究旨在探讨GB对改善3至6个月婴儿进食抵抗的效果。
本随机、对照、双盲临床试验对64名3至6个月有进食抵抗的婴儿进行，这些婴儿被转诊至儿科诊所并分为两组，每组32名。病例组在第一周给予5mg/kg的GB剂量，如果没有过度镇静，在第二周每8小时增加至10mg/kg，而对照组接受安慰剂。记录两组在用药2周前后有效母乳喂养的次数和配方奶的摄入量（单位：毫升）。
与安慰剂组相比，GB组母乳喂养次数的增加显著更高（中位数[四分位间距]：1[0,1]对0[0,1]，P = 0.005），并且配方奶摄入量也有所增加（均值±标准差：42.81±24.49对18.67±14.57，P = 0.003）。
考虑到GB组配方奶摄入量和母乳喂养次数的显著增加，有可能将这种药物用作神经稳定剂和止痛剂来治疗这种障碍。
